None listed
Conditions
Brief summary
Chronic kidney disease is a serious public health problem as it is one of the major causes of hospitalization worldwide. Despite receiving medical treatment, the outcomes remain either fast progression to dialysis or transplantation. The findings of the EMPEROR Reduced trial and DAPA CKD trials support our rationale to further explore the effects of the drug beyond the diabetic patients. we would further like to explore the effects on just CKD patients and how does this drug affect the progression of CKD. It is hypothesized that by including this drug with the standard of treatment, it will slow down the progression of Chronic kidney disease to next stage.
Interventions
This research will involve the patients taking 10mg orally (tablet) of empagliflozin daily.
The duration will be 90 days. The adherence will be monitored by asking the patients to bring back the empty tablet package material with them.
Sponsors
Zara Nisar
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Non-diabetic CKD patients, stage 3&4. Age greater than or equal to 18 years. Both male & females
Exclusion criteria
Major surgery during the last 6 months Pregnant or nursing mothers Patients on transplantation list Patients on dialysis Patients who are allergic to any drug Patients with malignancy
Outcome results
None listed